Answering the CDMO Shortage: A New Paradigm for Drug Development

April 26, 2021 Ravi Samavedam
Answering the CDMO Shortage: A New Paradigm for Drug Development Teaser

In this article, "Answering the CDMO Shortage: A New Paradigm for Drug Development" Daniel Dernbach, Vice President of Operations at Azzur Cleanrooms on Demand™, discusses the pharmaceutical industry's difficulties surrounding the shortage of contract manufacturing organizations (CMO) and contract development and manufacturing company (CDMO) facilities.

Read the full article featured in Drug Discovery & Development to find out answers regarding the severity of the CMO/CDMO capacity shortage, the advantages of finding a middle ground between building your own facility and outsourcing to the saturated market, and scaling out versus scaling up. 

click here to read more

Ravi Samavedam Headshot

Ravi Samavedam

Ravi Samavedam joined Azzur Group in 2012 and is a Biochemical Engineer with more than 20 years of experience. Prior to his appointment to Chief Innovation Officer (CINO), Ravi served as President of Azzur Cleanrooms on Demand™ and previously was a General Manager of Azzur Boston. Ravi has been a part of technical operations, quality, and validation departments at some of the world’s foremost pharmaceutical manufacturers. He is an expert in phase-appropriate cGMP implementation, process validation, supplier management, and technology transfer. Ravi is an active member of industry and peer groups, and he is a frequent speaker at industry events.
Connect On Linkedin